...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: BETonMACE Enrollment
7
Mar 21, 2017 04:22PM
7
Mar 24, 2017 03:15PM
3
Mar 24, 2017 03:34PM
2
Mar 25, 2017 10:41AM
4
Mar 25, 2017 11:14AM
2
Mar 25, 2017 02:27PM
5
Mar 25, 2017 04:07PM
6
Mar 26, 2017 03:01PM
3
Mar 28, 2017 03:07PM
3
Mar 28, 2017 03:26PM
2
Mar 28, 2017 03:39PM
4
Jun 28, 2017 10:37AM
6
Aug 28, 2017 12:56PM
3
Aug 28, 2017 01:57PM
1
Aug 28, 2017 02:16PM
2
Aug 28, 2017 03:09PM
3
Aug 28, 2017 10:05PM
6
Aug 29, 2017 08:00AM
4
Aug 29, 2017 09:29AM
6
Aug 30, 2017 06:18PM
3
Aug 30, 2017 07:30PM
3
Aug 30, 2017 08:17PM
15
Sep 02, 2017 12:03PM
2
Sep 02, 2017 12:45PM
3
Sep 02, 2017 02:06PM
3
Sep 02, 2017 02:21PM
5
Dec 14, 2017 04:51PM
3
Dec 15, 2017 12:32AM
7
Dec 15, 2017 11:40AM
4
Dec 15, 2017 01:00PM
2
Dec 15, 2017 02:25PM
4
Dec 15, 2017 07:33PM
3
Jan 11, 2018 02:40PM
6
Jan 11, 2018 03:01PM
3
Jan 11, 2018 03:29PM
2
Feb 28, 2018 03:21PM
7
Mar 01, 2018 11:38AM
1
Mar 01, 2018 02:17PM
4
Feb 08, 2019 10:07AM
2
Feb 08, 2019 04:50PM
4
Feb 08, 2019 11:03PM
1
Feb 09, 2019 02:43PM

Feb 09, 2019 03:31PM
3
Feb 09, 2019 03:52PM

Feb 09, 2019 04:14PM
1
Feb 09, 2019 08:00PM

"But don't all cardiac patients have elevated transaminase levels to start?"

BETonMACE already excludes patients with ALT/AST values greater than 1.5 times the upper limit of normal (ULN) at visit 1.

For more detail on the elevated ALT/AST data from the ASSURE study, see this document, which throughly documents adverse events and ALT/AST values from ASSURE. A summary of the ALT/AST observations in ASSURE is below (RVX000222=apabetalone):

"There were no clinically significant observations in laboratory results, with the exception of ALT/AST elevations, which occurred more frequently in the RVX000222 group compared with placebo (42.0% vs. 22.5%, p=0.002). In the RVX000222 group, 7.0% (17/243) had ALT elevations >3x ULN; among patients with any ALT elevation, 9.3% (9/97) had elevations >5x ULN. In the RVX000222 group, 4.1% (10/243) had AST elevations >3x ULN; among patients with any AST elevation, 7.0% (5/71) had elevations >5x ULN."

Also from the 2015 AGM (transcript courtesy of imtesty):

"We think we’re getting to the bottom of this adverse event. We’ve done a lot of work in the laboratory to investigate this. And we seem to see that there is a change in bile acid metabolism in selected patients, because BET inhibition does change the expression of bile transporters and bile enzymes in selected individuals. So there’s an increase in influx of cholesterol, and a change in bile pathway, and a down regulation, transient. But this down-regulation does not persist for long; there is an adaption within the liver cell, which accounts for why the enzyme levels go away with continued therapy. The net effect is an increase in bile acids in a very small number of patients. And we’re working in the lab to confirm this hypothesis. One of the reasons behind our BETonMACE study, apart from outcomes, is to get a very large safety database, to truly document the incidence and the consequences of these hepatic enzyme increases."

If interested, more tidbits on this apabetalone/aminotransferase/bile acid/FXR relationship in this post.

BearDownAZ

 

2
Feb 10, 2019 12:33PM
1
Feb 11, 2019 09:05AM
1
Feb 22, 2019 04:10PM
3
Feb 22, 2019 05:31PM
3
Feb 22, 2019 10:59PM
5
Feb 23, 2019 02:33PM
1
Aug 18, 2019 10:29AM
5
Aug 18, 2019 01:02PM
3
Aug 18, 2019 01:47PM
2
Aug 18, 2019 01:57PM
3
Aug 18, 2019 02:26PM
3
Aug 18, 2019 02:28PM
3
Aug 18, 2019 04:41PM
2
Aug 18, 2019 04:59PM
3
Aug 18, 2019 06:54PM
3
Aug 18, 2019 07:04PM
4
Aug 18, 2019 08:24PM
Share
New Message
Please login to post a reply